IDO1 and non-small cell lung carcinoma: Metabolic processinggenes, indoleamine 2,3-dioxygenase 1 (IDO1) and fatty acid synthase(FASN), were also both DEGs in both NSCLC subtypes relative to PBMCsand for which targeting drugs are either approved or in clinical trials.47